{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:52:26Z","timestamp":1790409146433,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T00:00:00Z","timestamp":1546992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1038\/s41417-018-0070-x","type":"journal-article","created":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T17:46:48Z","timestamp":1546883208000},"page":"347-355","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["High expression of UBE2T predicts poor prognosis and survival in multiple myeloma"],"prefix":"10.1038","volume":"26","author":[{"given":"Weilong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuozhen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoni","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4448-5399","authenticated-orcid":false,"given":"Xue","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,9]]},"reference":[{"key":"70_CR1","first-page":"373","volume":"95","author":"TC Michels","year":"2017","unstructured":"Michels TC, Petersen KE. Multiple myeloma: diagnosis and treatment. Am Fam Physician. 2017;95:373\u201383.","journal-title":"Am Fam Physician"},{"key":"70_CR2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","volume":"43","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43:676\u201381.","journal-title":"Semin Oncol"},{"key":"70_CR3","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","volume":"15","author":"SK Kumar","year":"2018","unstructured":"Kumar SK, Rajkumar SV. The multiple myelomas\u2014current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol. 2018;15:409\u201321.","journal-title":"Nat Rev Clin Oncol"},{"key":"70_CR4","doi-asserted-by":"crossref","unstructured":"Bergsagel PL. Where we were, where we are, where we are going: progress in multiple myeloma. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting in Chicago 2014: 199\u2013203.","DOI":"10.14694\/EdBook_AM.2014.34.199"},{"key":"70_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/leu.2008.291","volume":"23","author":"RA Kyle","year":"2009","unstructured":"Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3\u20139.","journal-title":"Leukemia"},{"key":"70_CR6","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","volume":"374","author":"MS Raab","year":"2009","unstructured":"Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet (Lond, Engl). 2009;374:324\u201339.","journal-title":"Lancet (Lond, Engl)"},{"key":"70_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1586\/17474086.2014.870030","volume":"7","author":"RA Kyle","year":"2014","unstructured":"Kyle RA, Rajkumar SV. An overview of the progress in the treatment of multiple myeloma. Expert Rev Hematol. 2014;7:5\u20137.","journal-title":"Expert Rev Hematol"},{"key":"70_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4103\/jomt.jomt_8_18","volume":"20","author":"OJ Egesie","year":"2018","unstructured":"Egesie OJ, Agaba PA, Silas OA, Achenbach C, Zoakah A, Agbaji OO, et al. Presentation and survival in patients with hematologic malignancies in Jos, Nigeria: a retrospective cohort analysis. J Med Trop. 2018;20:49\u201356.","journal-title":"J Med Trop"},{"key":"70_CR9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/leu.2013.247","volume":"28","author":"WJ Chng","year":"2014","unstructured":"Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28:269\u201377.","journal-title":"Leukemia"},{"key":"70_CR10","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol"},{"key":"70_CR11","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020\u20138.","journal-title":"Blood"},{"key":"70_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s12032-014-0093-6","volume":"31","author":"MJ Zhou","year":"2014","unstructured":"Zhou MJ, Chen FZ, Chen HC. Ubiquitination involved enzymes and cancer. Med Oncol (North, Lond, Engl). 2014;31:93.","journal-title":"Med Oncol (North, Lond, Engl)"},{"key":"70_CR13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1673-8527(07)60065-4","volume":"34","author":"Y Zhang","year":"2007","unstructured":"Zhang Y, Zhou X, Huang P. Fanconi anemia and ubiquitination. J Genet Genom=Yi chuan xue bao. 2007;34:573\u201380.","journal-title":"J Genet Genom=Yi chuan xue bao"},{"key":"70_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.celrep.2015.06.014","volume":"12","author":"KA Rickman","year":"2015","unstructured":"Rickman KA, Lach FP, Abhyankar A, Donovan FX, Sanborn EM, Kennedy JA. et al. Deficiency of UBE2T, the E2 ubiquitin ligase necessary for FANCD2 and FANCI ubiquitination, causes FA-T subtype of fanconianemia. Cell Rep. 2015;12:35\u201341.","journal-title":"Cell Rep"},{"key":"70_CR15","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s00018-015-2129-2","volume":"73","author":"KH Lim","year":"2016","unstructured":"Lim KH, Song MH, Baek KH. Decision for cell fate: deubiquitinating enzymes in cell cycle checkpoint. Cell Mol life Sci. 2016;73:1439\u201355.","journal-title":"Cell Mol life Sci"},{"key":"70_CR16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.molcel.2006.06.024","volume":"23","author":"YJ Machida","year":"2006","unstructured":"Machida YJ, Machida Y, Chen Y, Gurtan AM, Kupfer GM, D\u2019Andrea AD, et al. UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol Cell. 2006;23:589\u201396.","journal-title":"Mol Cell"},{"key":"70_CR17","doi-asserted-by":"publisher","first-page":"8752","DOI":"10.1158\/0008-5472.CAN-09-1809","volume":"69","author":"T Ueki","year":"2009","unstructured":"Ueki T, Park JH, Nishidate T, Kijima K, Hirata K, Nakamura Y, et al. Ubiquitination and downregulation of BRCA1 by ubiquitin-conjugating enzyme E2T overexpression in human breast cancer cells. Cancer Res. 2009;69:8752\u201360.","journal-title":"Cancer Res"},{"key":"70_CR18","doi-asserted-by":"crossref","first-page":"15161","DOI":"10.18632\/oncotarget.7805","volume":"7","author":"W Hu","year":"2016","unstructured":"Hu W, Xiao L, Cao C, Hua S, Wu D. UBE2T promotes nasopharyngeal carcinoma cell proliferation, invasion, and metastasis by activating the AKT\/GSK3beta\/beta-catenin pathway. Oncotarget. 2016;7:15161\u201372.","journal-title":"Oncotarget"},{"key":"70_CR19","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/nbt.1665","volume":"28","author":"L Shi","year":"2010","unstructured":"Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol. 2010;28:827\u201338.","journal-title":"Nat Biotechnol"},{"key":"70_CR20","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","volume":"128","author":"N Weinhold","year":"2016","unstructured":"Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, et al. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016;128:1735\u201344.","journal-title":"Blood"},{"key":"70_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ccr.2012.12.001","volume":"23","author":"W Zhou","year":"2013","unstructured":"Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W, et al. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell. 2013;23:48\u201362.","journal-title":"Cancer Cell"},{"key":"70_CR22","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1182\/blood-2009-12-261032","volume":"116","author":"A Broyl","year":"2010","unstructured":"Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010;116:2543\u201353.","journal-title":"Blood"},{"key":"70_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09378-9","volume":"7","author":"B Miannay","year":"2017","unstructured":"Miannay B, Minvielle S, Roux O, Drouin P, Avet-Loiseau H, Guerin-Charbonnel C, et al. Logic programming reveals alteration of key transcription factors in multiple myeloma. Sci Rep. 2017;7:9257.","journal-title":"Sci Rep"},{"key":"70_CR24","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1182\/blood-2006-09-044974","volume":"109","author":"G Mulligan","year":"2007","unstructured":"Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007;109:3177\u201388.","journal-title":"Blood"},{"key":"70_CR25","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","volume":"22","author":"D Chauhan","year":"2012","unstructured":"Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, Carrasco R, et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012;22:345\u201358.","journal-title":"Cancer Cell"},{"key":"70_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"W Huang da","year":"2009","unstructured":"Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44\u201357.","journal-title":"Nat Protoc"},{"key":"70_CR27","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMra041875","volume":"351","author":"RA Kyle","year":"2004","unstructured":"Kyle RA, Rajkumar SV. Multiple myeloma. N Eng J Med. 2004;351:1860\u201373.","journal-title":"N Eng J Med"},{"key":"70_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1182\/blood-2003-04-1045","volume":"103","author":"B Barlogie","year":"2004","unstructured":"Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, et al. Treatment of multiple myeloma. Blood. 2004;103:20\u201332.","journal-title":"Blood"},{"key":"70_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25:91\u2013101.","journal-title":"Cancer Cell"},{"key":"70_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3997","volume":"5","author":"N Bolli","year":"2014","unstructured":"Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997.","journal-title":"Nat Commun"},{"key":"70_CR31","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","volume":"385","author":"C Rollig","year":"2015","unstructured":"Rollig C, Knop S, Bornhauser M. Multiple myeloma. Lancet (Lond, Engl). 2015;385:2197\u2013208.","journal-title":"Lancet (Lond, Engl)"},{"key":"70_CR32","doi-asserted-by":"publisher","first-page":"5657","DOI":"10.1093\/nar\/gku198","volume":"42","author":"S Longerich","year":"2014","unstructured":"Longerich S, Kwon Y, Tsai MS, Hlaing AS, Kupfer GM, Sung P. Regulation of FANCD2 and FANCI monoubiquitination by their interaction and by DNA. Nucleic Acids Res. 2014;42:5657\u201370.","journal-title":"Nucleic Acids Res"},{"key":"70_CR33","doi-asserted-by":"crossref","first-page":"32639","DOI":"10.18632\/oncotarget.15947","volume":"8","author":"C Luo","year":"2017","unstructured":"Luo C, Yao Y, Yu Z, Zhou H, Guo L, Zhang J, et al. UBE2T knockdown inhibits gastric cancer progression. Oncotarget. 2017;8:32639\u201354.","journal-title":"Oncotarget"},{"key":"70_CR34","doi-asserted-by":"crossref","first-page":"25226","DOI":"10.18632\/oncotarget.4712","volume":"6","author":"M Wen","year":"2015","unstructured":"Wen M, Kwon Y, Wang Y, Mao JH, Wei G. Elevated expression of UBE2T exhibits oncogenic properties in human prostate cancer. Oncotarget. 2015;6:25226\u201339.","journal-title":"Oncotarget"},{"key":"70_CR35","doi-asserted-by":"publisher","first-page":"e0181447","DOI":"10.1371\/journal.pone.0181447","volume":"12","author":"J Li","year":"2017","unstructured":"Li J, Wang N, Tesfaluul N, Gao X, Liu S, Yue B. Prognostic value of circulating plasma cells in patients with multiple myeloma: a meta-analysis. PLoS ONE. 2017;12:e0181447.","journal-title":"PLoS ONE"},{"key":"70_CR36","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.4103\/0366-6999.231513","volume":"131","author":"L Wang","year":"2018","unstructured":"Wang L, Jin FY, Li Y, Sun JN, Zhang JJ, Tang R, et al. IgA type multiple myeloma, clinical features, and prognosis. Chin Med J. 2018;131:1249\u201350.","journal-title":"Chin Med J"},{"key":"70_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/hon.2018","volume":"31","author":"N Grzasko","year":"2013","unstructured":"Grzasko N, Hus M, Pluta A, Jurczyszyn A, Walter-Croneck A, Morawska M, et al. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. Hematol Oncol. 2013;31:41\u20138.","journal-title":"Hematol Oncol"},{"key":"70_CR38","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","volume":"109","author":"F Zhan","year":"2007","unstructured":"Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007;109:1692\u2013700.","journal-title":"Blood"},{"key":"70_CR39","first-page":"6094","volume":"15","author":"B Zhu","year":"2018","unstructured":"Zhu B, Ju S, Chu H, Shen X, Zhang Y, Luo X, et al. The potential function of microRNAs as biomarkers and therapeutic targets in multiple myeloma. Oncol Lett. 2018;15:6094\u2013106.","journal-title":"Oncol Lett"},{"key":"70_CR40","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","volume":"12","author":"JJ Keats","year":"2007","unstructured":"Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007;12:131\u201344.","journal-title":"Cancer Cell"},{"key":"70_CR41","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","volume":"125","author":"G Bianchi","year":"2015","unstructured":"Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015;125:3049\u201358.","journal-title":"Blood"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41417-018-0070-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41417-018-0070-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41417-018-0070-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:10:08Z","timestamp":1684602608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-018-0070-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,9]]},"references-count":41,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["70"],"URL":"https:\/\/doi.org\/10.1038\/s41417-018-0070-x","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,9]]},"assertion":[{"value":"11 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}